XPC and lung adenocarcinoma: The results showed that the overall survival time of lung adenocarcinoma patients with high XPC expression was longer than that of lung adenocarcinoma patients with low XPC expression (Log-rank p = 0.0577) (Figure 3A), and the overall survival time of lung adenocarcinoma patients with high CD133 expression was lower than that of lung adenocarcinoma patients with low CD133 expression (Log-rank p = 0.00417) (Figure 3B).